antibody-drug conjugates

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

Market Access

Six takeaways from JP Morgan 2024

With another JP Morgan in the rearview mirror, it’s time to take stock of the announcements, the presentations, and, above all, the vibes.

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

R&D